Board of Directors recommends a dividend at the rate of ₹ 75 per equity share for the 12 months period ended March 31, 2018
GlaxoSmithKline Consumer Healthcare has declared its financial results for the fourth quarter and full year ended March 31, 2018. The comparable revenue for the company recorded a growth of 8 per cent. The quarter reported revenue of ₹ 1,180 crore, while the PBT is at ₹ 319 crores, which is an increase by 18.3 per cent compared to last quarter. The quarter also witnessed a volume growth at 5.3 per cent. For the full year, the comparable revenue is ₹ 4,377 crores which is an increase by 7.6 per cent and the PBT is at ₹ 1,074 crores, which is an increase by 6.3 per cent compared to last year.
The Board of Directors of the company recommended a dividend at the rate of ₹ 75 per equity share of Rs 10 each for the year ended March 31, 2018.
Commenting on the results, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare said, “I am satisfied with the overall quarter performance specially on volume growth in our health drinks portfolio and the share gain achieved by our lead brand Horlicks. The quarter witnessed the launch of Protein+, an advanced nutrition product, that will significantly strengthen our position in the high-science range and will further reinforce our leadership in the HFD category.”
“As a company, we remain committed to driving the nutrition agenda for the country through various initiatives which are also in line with Government’s National Nutrition Mission. We remain committed to our ACCESS & REACH agenda. Our rural coverage across nine states where we operate has increased to 21,500 villages through rural sub distributors and Village Level Entrepreneurs (VLE’s). Now we reach to around 3.5 lakh outlets directly in this channel. With a strong government focus on nutrition, better than expected monsoons and an improved business environment, we are bullish about the coming quarters,” added Saluja.